Last $27.91 USD
Change Today +0.03 / 0.11%
Volume 775.7K
AMED On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

amedisys inc (AMED) Snapshot

Open
$27.85
Previous Close
$27.88
Day High
$28.60
Day Low
$27.44
52 Week High
12/19/14 - $28.60
52 Week Low
05/8/14 - $12.86
Market Cap
931.6M
Average Volume 10 Days
324.7K
EPS TTM
$0.22
Shares Outstanding
33.4M
EX-Date
--
P/E TM
125.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for AMEDISYS INC (AMED)

amedisys inc (AMED) Related Businessweek News

View More BusinessWeek News

amedisys inc (AMED) Details

Amedisys Inc. provides home health and hospice services including practical nursing services and physical and occupational therapy. The company’s services also comprise speech pathology, social work to help families address acute and chronic illnesses, home health aide services, and private duty services. Hospice services use a team made up of a physician, patient care manager, registered nurses, certified home health aides, social workers, a chaplain, a homemaker, and volunteers. As of Apr. 4, 2007, the company operated 261 Medicare-certified home health agencies and 14 Medicare-certified hospice agencies in 19 states. Amedisys was founded in 1982 and is headquartered in Baton Rouge, La.

14,300 Employees
Last Reported Date: 03/12/14
Founded in 1982

amedisys inc (AMED) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $308.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $277.3K
Chief Compliance Officer and Corporate Counse...
Total Annual Compensation: $270.6K
Compensation as of Fiscal Year 2013.

amedisys inc (AMED) Key Developments

Amedisys Inc. Announces Management Changes

Amedisys Inc. announced that its Board of Directors has named Paul B. Kusserow as President and Chief Executive Officer and member of the Board of Directors. Kusserow will assume the role on December 16, 2014 from President and Interim CEO, Ronald LaBorde, who will remain a member of the senior management team in the role of Vice Chairman reporting directly to the CEO. LaBorde will also continue to serve as a member of the Board of Directors. Kusserow was most recently Vice Chairman of Alignment Healthcare Inc. Before that, he served as Senior Vice President, Chief Strategy, Innovations and Corporate Development Officer of Humana Inc.

Amedisys Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 08:35 AM

Amedisys Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 08:35 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Dale E. Redman, Interim Chief Financial Officer.

Amedisys Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Capital Expenditures Guidance for the Fourth Quarter and Full Year of 2014; Reports Write-Off for the Quarter Ended September 30, 2014

Amedisys Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net service revenue of $300,281,000 compared to $301,285,000 a year ago. Operating income was $16,248,000 compared to operating loss of $154,226,000 a year ago. Income before income taxes were $13,955,000 compared to loss before income taxes of $147,973,000 a year ago. Income from continuing operations was $8,597,000 compared to loss from continuing operations of $91,045,000 a year ago. Net income was $8,597,000 compared to net loss of $91,778,000 a year ago. Net income attributable to the company was $8,439,000 compared to net loss attributable to the company of $91,069,000 a year ago. Basic and diluted net income per share attributable to the company was $0.26 compared to basic and diluted net loss per share attributable to the company of $2.89 a year ago. Net cash provided by operating activities was $25,342,000 compared to $27,885,000 a year ago. EBITDA was $23,278,000 compared to LBITDA of $137,685,000 a year ago. Adjusted EBITDA was $23,793,000 compared to $8,804,000 a year ago. Adjusted net income from continuing operations attributable to the company was $9,057,000 compared to adjusted net loss from continuing operations attributable to the company of $155,000 a year ago. Adjusted diluted earnings per share were $0.28 compared to adjusted diluted loss per share of $0.01 a year ago. The company spent less than $1 million on capital expenditures in the quarter. For the nine months, the company reported net service revenue of $904,026,000 compared to $945,847,000 a year ago. Operating income was $9,236,000 compared to operating loss of $144,609,000 a year ago. Income before income taxes were $6,457,000 compared to loss before income taxes of $139,918,000 a year ago. Income from continuing operations was $3,974,000 compared to loss from continuing operations of $86,182,000 a year ago. Net income was $3,758,000 compared to net loss of $87,797,000 a year ago. Net income attributable to the company was $3,641,000 compared to net loss attributable to the company of $86,549,000 a year ago. Basic and diluted net income per share attributable to the company was $0.11 compared to basic and diluted net loss per share attributable to the company of $2.78 a year ago. Net cash used in operating activities was $70,129,000 compared to net cash provided by operating activities of $93,862,000 a year ago. EBITDA was $34,006,000 compared to LBITDA of $107,926,000 a year ago. Adjusted EBITDA was $51,405,000 compared to $46,727,000 a year ago. Adjusted net income from continuing operations attributable to the company was $14,875,000 compared to $10,276,000 a year ago. Adjusted diluted earnings per share were $0.46 compared to $0.33 a year ago. The company spent $10 million for the year-to-date on capital expenditures. For the year 2014, the company expects capital expenditures to be approximately $15 million. The company now believes to incur $5 million of capital expenditure in the fourth quarter of 2014, largely driven by planned refresh of tablets used by clinicians. There were two non-cash write-offs in the quarter totaling $1 million or $0.02 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMED:US $27.91 USD +0.03

AMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almost Family Inc $29.85 USD -0.45
BioScrip Inc $6.12 USD -0.035
Chemed Corp $106.52 USD -0.32
LHC Group Inc $29.63 USD -0.20
SunLink Health Systems Inc $1.38 USD -0.01
View Industry Companies
 

Industry Analysis

AMED

Industry Average

Valuation AMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 2.4x
Price/Cash Flow 37.7x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMEDISYS INC, please visit www.amedisys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.